Filing scope and business context
Entity mismatch: The filing is Integrity Applications, Inc.’s Form 10-K, not a filing under the name Glucotrack, Inc. The company’s product is GlucoTrack. This is an annual report for the fiscal year ended December 31, 2016, not a standalone fourth-quarter report; the filing was signed March 31, 2017.
Integrity develops and commercializes GlucoTrack DF-F, a non-invasive, earlobe-based glucose monitor. It had CE Mark authorization and received final South Korean approval in October 2016, but had no U.S. marketing approval. Sales were early-stage and primarily through distributors.
Financial performance and condition
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | $611,689 | $143,167 |
| Operating expenses | $6,267,531 | $4,798,520 |
| Operating loss | $5,655,842 | $4,655,353 |
| Net loss | $5,409,737 | $5,842,172 |
| Net cash used in operating activities | $5,311,830 | $4,565,224 |
- Revenue increased about 327% year over year, but remained small relative to operating costs. The filing does not provide a clear gross-profit or gross-margin figure; operating margin was approximately negative 925%.
- R&D expense rose to $2.88 million from $2.27 million, mainly due to staffing and China regulatory work. G&A increased to $2.26 million from $1.40 million, including higher compensation, board costs and a $211,077 one-time warrant-related charge. Sales and marketing was essentially unchanged at $1.13 million.
- Year-end cash and equivalents were $148,836, down from $608,701. Current assets were $2.02 million versus current liabilities of $2.35 million. Total assets were $2.46 million; total liabilities were $3.37 million. Stockholders’ deficit was $10.95 million and accumulated deficit was $35.60 million.
- Long-term stockholder loans were $162,034; the company reported an unused, secured bank credit line of approximately $38,500. Preferred stock of $10.04 million was classified as temporary equity, not ordinary shareholders’ equity, and carries dividends and potential redemption rights.
- FY 2016 financing activities provided $4.94 million, principally from Series C financing. After year-end, the company reported approximately $7.1 million of net Series C proceeds during Q1 2017 and cash of approximately $1.635 million as of March 27, 2017. Management said that, even with that financing, cash was expected to fund less than six months of operations from the report date.
Changes, outlook and material risks
- Devices totaling $400,000 were delivered and fully paid for in 2016. The company reported approximately $1.9 million in orders, but $1.5 million remained contingent on local regulatory approvals, had no prepayments, and might not be fulfilled. The initial South Korean distributor order was 100 devices, reported as $100,000 of fourth-quarter revenue.
- The company reported favorable results from limited clinical studies, including 99.7% of data points in the Consensus Error Grid A/B zones and 17.0% mean absolute relative difference. These are company-reported study results, not evidence of U.S. approval or broad commercial performance.
- Management expected U.S. clinical trials to begin in the first half of 2017, subject to completing site agreements and obtaining financing. FDA feedback verbally characterized the planned trials as non-significant risk; the device itself was not FDA-cleared or approved. China’s regulator required additional trials, extending the expected review by 17–23 months or longer.
- Wistron’s production line received Taiwanese regulatory clearance in January 2017. Commercial manufacturing nevertheless depends on third parties, and sales depend on distributor execution and country-level approvals.
- The auditor and management cited substantial doubt about the company’s ability to continue as a going concern. The company had no material recurring revenue, negative operating cash flow and continuing dependence on external financing. Additional equity financing could materially dilute shareholders; preferred-stock terms include anti-dilution provisions, dividends, covenants and possible redemption obligations.
- Other key risks include product accuracy and market acceptance, reimbursement and pricing, competition, customer and supplier concentration (four customers represented about 90% of 2016 sales; one vendor about 77% of purchases), and reliance on Israeli operations and third-party manufacturing.
- Management did not provide revenue or earnings guidance. Product development, U.S. trials, China approval and further commercialization plans were conditional on financing and regulatory progress.
Most important facts for investors to verify
- Confirm the issuer identity and ticker: the supplied filing is for Integrity Applications, Inc. (OTCQB: IGAP), despite the request metadata naming Glucotrack, Inc.
- Reconcile the financing amounts and timing: FY 2016 net Series C proceeds were approximately $4.95 million; additional Q1 2017 proceeds and the reported March 27 cash balance are subsequent events.
- Track cash burn, required financing and going-concern status, including whether subsequent funding extended the stated runway.
- Verify conversion of the $1.5 million contingent order backlog into paid deliveries, and distinguish booked revenue from conditional orders.
- Monitor U.S. clinical-trial initiation and results, FDA pathway and approval status, China’s additional-trial requirements, and local approvals in distributor territories.
- Assess fully diluted share count and preferred-stock/warrant terms, including potential dilution, dividends, anti-dilution adjustments and redemption triggers.